Aortic & peripheral vascular diseaseResearch article
Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification
- Narrative review
Authors' conclusion
Despite recent progress, clinical management remains limited by diagnostic uncertainty, heterogeneous treatment approaches, and a paucity of high-quality randomized controlled trials.
Study context
- Population
- Takayasu arteritis (TAK), a rare immune-mediated large-vessel vasculitis affecting predominantly young women
Main finding
As reported in the abstract
Treatment of Takayasu arteritis and CV risk reduction (narrative review)
- Relapse rates are high with glucocorticoids and conventional immunosuppressive therapies; current strategies fail to adequately mitigate future CV risk
- CV morbidity increasingly recognised as a major contributor to mortality in TAK
- Clinical management limited by diagnostic uncertainty, heterogeneous treatment approaches and a paucity of high-quality RCTs
Original publication
Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification. Circulation. Published 26 January 2026. doi:10.1161/circulationaha.125.076308
Summarised from the published abstract; every number is checked against it